Literature DB >> 15570193

Assessment of thiopurine methyltransferase and metabolite formation during thiopurine therapy: results from a large Swedish patient population.

Ulf Hindorf1, Curt Peterson, Sven Almer.   

Abstract

This study examined thiopurine methyltransferase (TPMT) and the relationship to thioguanine nucleotides (TGN) and methylthioinosine monophosphate (meTIMP) in a large Swedish patient population. The current hypothesis is that the cytotoxic effects of thiopurine drugs are mediated by the incorporation of TGN into DNA. The authors assayed the TPMT activity in red blood cells from 1151 subjects and the concentrations of TGN (n = 602) and meTIMP (n = 593) from patients treated with thiopurine drugs. The TPMT frequency distribution in both adults and children showed some differences from what had been found in unselected general populations. Children had lower median TPMT activity than adults (12.0 versus 12.9 U/mL RBC; P < 0.001). Relative differences in both TGN formation [medians: normal TPMT, 1.3; intermediate TPMT, 3.3; low TPMT, 47.9 pmol/8 x 10(8) RBC per mg azathioprine (AZA); P < 0.001] and meTIMP formation (medians: normal TPMT, 13; intermediate TPMT, 7.3; low TPMT, 0 pmol/8 x 10(8) RBC per mg AZA; P = 0.001) per 1 mg administered drug were noted among the 3 TPMT activity groups. Women formed higher concentrations of both TGN (1.5 versus 1.3 pmol/8 x 10(8) RBC per mg AZA; P = 0.01) and meTIMP (14.4 versus 10.7 pmol/8 x 10(8) RBC per mg AZA; P = 0.01) than men did. There was a significant correlation between the AZA dose and the meTIMP concentrations (r = 0.45; P < 0.001). Furthermore, dose alterations made in subjects with normal TPMT (n = 84) and intermediate TPMT (n = 22) activity resulted in more pronounced increases in TGN concentrations (170 versus 30 pmol/8 x 10(8) RBC; P < 0.001) in intermediate TPMT activity, whereas in normal TPMT activity changes in meTIMP concentrations were more pronounced (1.3 versus 0 nmol/8 x 10(8) RBC; P < 0.001). In normal TPMT activity both metabolites increased in a dose-dependent fashion, whereas in intermediate TPMT activity only TGN concentrations increased. The results of this study demonstrate the dynamic nature of thiopurine metabolism and its importance for thiopurine dosing.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15570193     DOI: 10.1097/00007691-200412000-00014

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  6 in total

1.  Modeling the Outcome of Systematic TPMT Genotyping or Phenotyping Before Azathioprine Prescription: A Cost-Effectiveness Analysis.

Authors:  Kevin Zarca; Isabelle Durand-Zaleski; Marie-Anne Loriot; Gilles Chatellier; Nicolas Pallet
Journal:  Mol Diagn Ther       Date:  2019-06       Impact factor: 4.074

2.  Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease.

Authors:  U Hindorf; M Lindqvist; C Peterson; P Söderkvist; M Ström; H Hjortswang; A Pousette; S Almer
Journal:  Gut       Date:  2006-03-16       Impact factor: 23.059

3.  IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations.

Authors:  Sofie Haglund; Jan Taipalensuu; Curt Peterson; Sven Almer
Journal:  Br J Clin Pharmacol       Date:  2007-07-27       Impact factor: 4.335

4.  Optimal chemotherapy for leukemia: a model-based strategy for individualized treatment.

Authors:  Devaraj Jayachandran; Ann E Rundell; Robert E Hannemann; Terry A Vik; Doraiswami Ramkrishna
Journal:  PLoS One       Date:  2014-10-13       Impact factor: 3.240

Review 5.  Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use.

Authors:  Vid Mlakar; Patricia Huezo-Diaz Curtis; Chakradhara Rao Satyanarayana Uppugunduri; Maja Krajinovic; Marc Ansari
Journal:  Int J Mol Sci       Date:  2016-09-08       Impact factor: 5.923

Review 6.  Thiopurine monitoring in children with inflammatory bowel disease: a systematic review.

Authors:  Anastasia Konidari; Antonios Anagnostopoulos; Laura J Bonnett; Munir Pirmohamed; Wael El-Matary
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.